While numerous studies have been carried out to repurpose parameters such as mid-regional pro-adrenomedullin (MR-pro-ADM), monocyte distribution width, or various micro RNAs (miRNAs) as novel biomarkers for predicting the risk of COVID-19 severity, limitations experienced with each of them indicate that there is still need for the identification of a better biomarker (8, 9). Here, ADM is linked to COVID-19.